Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.

F. Giles,Michael J. Mauro,Frank Hong,Christine-Elke Ortmann,C. McNeill,Richard C. Woodman,Andreas Hochhaus,P. le Coutre,G. Saglio

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.

2013

F. Giles
Michael J. Mauro
Frank Hong
Christine-Elke Ortmann
C. McNeill
Richard C. Woodman
Andreas Hochhaus
P. le Coutre
G. Saglio

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis

Keywords:

Nilotinib
Cancer research
Myeloid leukemia
Ponatinib
Retrospective cohort study
Leukemia
Tyrosine-kinase inhibitor
Tyrosine kinase
Oncology
Immunology
Imatinib
Medicine
Internal medicine
Cohort

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

161

Citations